FDA granted accelerated approval to Tagrisso (osimertinib) tablets for the treatment of patients with metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer, as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor therapy.
Sidney Kimmel Cancer Center at Jefferson Health can add the word “Comprehensive” to its name, becoming the 57 institution to earn this top-level designation from NCI. xxx:more
